Syros Pharma in-licenses clinical-stage RARα agonist from TMRC
US privately-held industry pioneer in gene control Syros Pharmaceuticals has entered into an exclusive license agreement with the Japanese oncology company TMRC Co, to develop and commercialize tamibarotene in North America and Europe for cancer. Financial terms of the agreement were not disclosed.
Tamibarotene is a first-in-class selective agonist to retinoic acid receptor alpha (RARα), a nuclear hormone receptor which regulates transcription. Using Syros’ proprietary gene control discovery and development platform, the company discovered a cancer dependency to RARα and a biomarker to identify patients with this dependency who may respond to RARα agonist therapy. Syros plans to initiate a Phase II clinical trial with tamibarotene in the first half of 2016 in this genomically-defined subset of patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).
Tamibarotene currently marketed as APL treatment in Japan
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze